Management remarks
Call period: 2026 Q2 · 2026-08-04
Guidance: Andrew Dickinson: Within HIV, we now expect full year sales to grow between 9% and 10% year-over-year, up from 8% previously, driven by continued strong growth in Biktarvy for HIV treatment as well as Yeztugo and Descovy for PrEP.Demand and orders: Johanna Mercier: Biktarvy sales of $3.8 billion were up 7% year-over-year, driven by higher average realized price due to channel mix in addition to inventory build and higher demand. Sequentially, Biktarvy sales increased 12%, driven by typical seasonality, partially offset by lower demand due to market dynamics, including a greater-than-expected impact associated with changes in the Affordable Care Act.Margins: Andrew Dickinson: Product gross margin was 87%, flat year-over-year and in line with our full year guidance.Analyst Q&A
Analyst Geoffrey Meacham asked: Or has that become less of a priority as long as you just have strong growth, cash flow, improving margins, et cetera? Management Daniel O'Day answered: In the treatment area, of course, it's going to start with this BIC/LEN. We expect approval by the end of this month, another daily oral option to kind of capture the switch market within Gilead. And then, of course, once weekly, once monthly, once every 6 months and once a year across the treatment and PrEP portfolio, which we think is durable and long-lasting well into the end of the next decade. So that's job #1 is to diversify that.管理层陈述
电话会期间：2026 Q2 · 2026-08-04
指引：安德鲁·迪金森称：在HIV业务领域，我们预计全年销售额同比增长9%至10%，较此前的8%有所提升，这一增长由用于HIV治疗的必妥维（Biktarvy）以及用于PrEP的Yeztugo和Descovy的持续强劲增长推动。需求与订单：约翰娜·梅尔西耶称：必妥维（Biktarvy）销售额达38亿美元，同比增长7%，这得益于渠道组合带来的平均实现价格上涨、库存增加以及需求上升。按季度来看，必妥维销售额增长12%，由典型季节性因素推动，但被市场动态带来的需求下降部分抵消，其中包括《平价医疗法案》变化带来的超出预期的更大影响。利润率：安德鲁·迪金森称：产品毛利率为87%，同比持平，符合我们的全年毛利率指引。分析师问答
分析师杰弗里·米查姆问道：“或是只要你们能实现强劲增长、现金流和利润率改善等目标，该事项就已不再那么重要了？” 管理层丹尼尔·奥戴回答：“在治疗领域，项目将首先从BIC/LEN起步，我们预计本月底获批，推出另一款每日口服疗法以抢占转换市场。此外，我们还将在治疗和PrEP产品线中布局每周一次、每月一次、每6个月一次及每年一次的疗法，其生命周期将持续到下一个十年末，多元化该产品线是我们的首要任务。”This earnings-call research was prepared from company results, regulatory filings, financial statements, and earnings-call transcripts or official replays. It is for informational purposes only and does not constitute investment advice.这篇财报电话会研究基于公司公告、监管文件、财务报表，以及真实电话会文字稿或官方回放整理。内容仅供参考，不构成投资建议。
